Skip to main content
. 2014 Oct 30;6(5):1190–1200. doi: 10.4161/mabs.29889

Figure 6.

Figure 6.

Characterization of m860ADC. (A) Flow cytometry analysis of the binding of IgG1 m860, Trastuzumab and m860ADC to SK-BR-3 cells. As expected, the binding activity of IgG1 m860 to HER2 on SK-BR-3 was not affected by the drug (nAF) conjugation to N-glycans attached to Fc. (B) SDS-PAGE gel analysis of m860ADC and naked IgG1 m860 under reducing and non-reducing conditions.